Novare Capital Management LLC Has $3.12 Million Position in Eli Lilly and Company $LLY

Key Points

• Novare Capital Management LLC has increased its position in Eli Lilly and Company by 114.0%, owning 4,000 shares valued at approximately $3.12 million following a quarter where additional shares were purchased.
• Eli Lilly's recent earnings report revealed an EPS of $6.31, surpassing estimates and demonstrating a revenue increase of 37.6% year-over-year.
• Institutional investors collectively hold 82.53% of Eli Lilly's stock, highlighting strong institutional confidence in the company.

Novare Capital Management LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 114.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,000 shares of the company's stock after buying an additional 2,131 shares during the quarter. Novare Capital Management LLC's holdings in Eli Lilly and Company were worth $3,118,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Brighton Jones LLC lifted its stake in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd increased its holdings in Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company's stock valued at $352,000 after purchasing an additional 85 shares during the period. GAMMA Investing LLC increased its holdings in Eli Lilly and Company by 25.8% in the first quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock valued at $14,866,000 after purchasing an additional 3,696 shares during the period. Finally, Boston Trust Walden Corp increased its holdings in Eli Lilly and Company by 1.2% in the first quarter. Boston Trust Walden Corp now owns 3,284 shares of the company's stock valued at $2,712,000 after purchasing an additional 40 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $803.53 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a 50-day moving average of $753.09 and a 200-day moving average of $766.23. The company has a market cap of $760.51 billion, a PE ratio of 52.52, a P/E/G ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 in the last 90 days. Company insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LLY. Weiss Ratings restated a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. HSBC increased their price objective on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Leerink Partners reiterated a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $939.12.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.